Promising COVID-19 therapies on examples of some antiviral, immunomodulatory and natural substances use - review
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.029Keywords
COVID-19, SARS-CoV-2, lopiravir, remdesivir, darunavir, molnupiravir, favipiravir, chloroquine, hydrochloroquine, corticosteroids, interferons, natural therapyAbstract
COVID-19 is one of the biggest challenges to medicine ever. Because of its dissemination in population effective drug to cure it was needed. There were some trials on antiviral drugs like lopiravir/ritonavir, remdesivir, darunavir/cobicistat, favipiravir, molnupiravir, discovered originally in order to treat other diseases. Only remdesivir and molnupiravir seem to be beneficial for patients with COVID-19, both of them are approved in therapy in a large number of countries allover the world. [2]
Another very important group of drugs used in trials against COVID-19 was immunomodulatory drugs. Some of them, like chloroquine/hydrochloroquine was very promising, but finally there were no evidences of its benefits found. [2] Corticosteroids used in moderate and severe COVID-19 caused general improvement of clinical status and decreased mortality. Interesting and quite promising may be use of interferons but for now lack of evidences does not allow to make clear statement about its benefits.
There are some argumentations for natural methods of COVID-19 treatment. Dietary recommendations, vitamin and microelements supplementation may be helpful in the therapy and in addition may not have any adverse effects. Also, herbal mixtures, developed centuries ago in China found usage during COVID-19 pandemic. After analysis of thousands of cases Traditional Chinese Medicine can be considered as one of the most successful attempt in combating COVID-19. [6]
References
Mohd. Imran, Mandeep Kumar Arora , Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Saleh I. Alaqel, Mohammed Kanan Alshammari , Mohammed M. Alshehri , Ahmed Subeh Alshrari, Alreshidi Mateq Ali , Ahmed Muteb Al-shammeri , Bushra Dhuhayyan Alhazmi, Aishah Ali Harshan, Md. Tauquir Alam and Abida “Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19”, Molecules 2021, 26, 5795. https://doi.org/10.3390/molecules26195795
A. Bartoli, F. Gabrielli, T. Alicandro, F. Nascimbeni, P.Andreone “COVID‐19 treatment options: a difficult journey between failed attempts and experimental drugs” Internal and Emergency Medicine (2021) 16:281–308 https://doi.org/10.1007/s11739-020-02569-9
X. Xu, Y.K. Ong, D.Y.Wang“ Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines, Xu et al. Military Medical Research (2020) 7:22 https://doi.org/10.1186/s40779-020-00251-x
Y. Song, M. Zhang, L. Yin, K. Wang, Y. Zhou, M. Zhou, Y. Lu “COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)” International Journal of Antimicrobial Agents 56 (2020) 106080 https://doi.org/10.1016/j.ijantimicag.2020.106080
M. S. Barber, R. Barrett, R. D. Bradley, E. Walker “A naturopathic treatment approach for mild and moderate COVID-19: A retrospective chart review” Complementary Therapies in Medicine 63 (2021) 102788 https://doi.org/10.1016/j.ctim.2021.102788
Jun-ling Ren, Ai-Hua Zhang, Xi-Jun Wang “Traditional Chinese medicine for COVID-19 treatment” Pharmacological Research 155 (2020) 104743, https://doi.org/10.1016/j.phrs.2020.104743
B, Young, T. T. Tan, Y. S. Leo “The place for remdesivir in COVID-19 treatment” www.thelancet.com/infection Vol 21 January 2021, https://doi.org/10.1016/ S1473-3099(20)30911-7
S.U. Rehman, S. Ur Rehman, H. H. Yoo “COVID-19 challenges and its therapeutics” Biomedicine & Pharmacotherapy 142 (2021) 112015, https://doi.org/10.1016/j.biopha.2021.112015
A. Jayk Bernal, M.M. Gomes da Silva, D.B. Musungaie, E. Kovalchuk, A. Gonzalez, V. Delos Reyes, A. Martín-Quirós, Y. Caraco, A. Williams-Diaz, M.L. Brown, J. Du, A. Pedley, C. Assaid, J. Strizki, J.A. Grobler, H.H. Shamsuddin, R. Tipping, H. Wan, A. Paschke, J.R. Butterton, M.G. Johnson, and C. De Anda “Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients” The new england journal of medicine, DOI: 10.1056/NEJMoa2116044
Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Hajjar LA (2020) Effect of high vs low doses of chloro- quine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection: a randomized clinical trial. JAMA Netw Open 3(4):e208857–e208857
Word Health Organisation. Clinical management of severe acute respiratory infection when novel coronavirus (nCov) infection is suspected: interim guidance. 2020-Centers for Disease Control and Prevention, Interim Clinical Guidance for management of patients with confirmed 2019 novel coronavirus (SARS-CoV-2) infection
Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, Shum HP (2020) Triple combination of interferon beta-1b, lopi- navir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 395(10238):1695–1704
Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Kain KC (2003) Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290(24):3222–3228
A.C.K Lee J.R. Morling “COVID-19 vaccine dilemmas” Public Health 2022 Jan;202:10-11. doi: 10.1016/j.puhe.2021.01.009.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Krzysztof Bielewicz, Karolina Ryba, Anna Karaś, Kinga Kawałko, Kamil Pondel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 465
Number of citations: 0
